You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AG-221

Showing 1 - 25 of 733
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatic Impairment Trial in Miami, Orlando, Knoxville (Enasidenib)

Recruiting
  • Hepatic Impairment
  • Miami, Florida
  • +4 more
Nov 27, 2022

Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Baltimore, Maryland
  • +2 more
Feb 25, 2022

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

Recruiting
  • Leukemia
  • +2 more
  • Enasidenib mesylat dose escalation
  • Palo Alto, California
    Stanford Cancer Institute
May 12, 2022

Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Biopsy, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 30, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Leukemia, Myeloid, Acute Trial in Worldwide (AG-120, Azacitidine, AG-221)

Active, not recruiting
  • Leukemia, Myeloid, Acute
  • Duarte, California
  • +72 more
Aug 18, 2022

Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)

Suspended
  • Recurrent Acute Myeloid Leukemia
  • Enasidenib Mesylate
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Los Angeles, California
  • +3 more
Sep 27, 2022

Diabetes Type 2 Trial in Lund (AG+XOS+AXOS, Placebo Maltodextrin)

Recruiting
  • Diabetes Type 2
  • AG+XOS+AXOS
  • Placebo Maltodextrin
  • Lund, Sweden
    Biomedical Nutrition, Lund University and Department of Endocrin
Jan 18, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Bosutinib Monohydrate
  • +6 more
  • Duarte, California
    City of Hope Meidcal Center
Jun 7, 2022

Hepatic Impairment Trial in United States (Enasidenib)

Completed
  • Hepatic Impairment
  • Lakewood, Colorado
  • +4 more
Jul 16, 2020

Leukemia, Myeloid, Isocitrate Dehydrogenase Trial in Worldwide (AG-221, BSC, Azacitidine)

Active, not recruiting
  • Leukemia, Myeloid
  • Isocitrate Dehydrogenase
  • AG-221
  • +4 more
  • Los Angeles, California
  • +145 more
Jun 7, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Canada, United States (Enasidenib, Enasidenib

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Birmingham, Alabama
  • +17 more
Jun 21, 2021

Acute Myeloid Leukemia Trial in Summit (AG-221)

No longer available
  • Acute Myeloid Leukemia
  • AG-221
  • Summit, New Jersey
    Celgene
Oct 23, 2019

Previously Untreated Acute Myeloid Leukemia Trial in United States (biological, other, drug)

Recruiting
  • Previously Untreated Acute Myeloid Leukemia
  • Samalizumab (BAML-16-001-S1)
  • +32 more
  • Phoenix, Arizona
  • +18 more
Oct 17, 2022

Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to

Withdrawn
  • Blasts Under 5 Percent of Peripheral Blood White Cells
  • +4 more
  • Buffalo, New York
  • +1 more
Mar 8, 2021

Follicular Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

Active, not recruiting
  • Follicular Lymphoma
  • Feldkirch, Austria
  • +41 more
Jul 1, 2022

Relapsed Refractory Multiple Myeloma Trial in United States (Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib,

Recruiting
  • Relapsed Refractory Multiple Myeloma
  • Abemaciclib, dexamethasone, ixazomib, pomalidomide
  • +7 more
  • Phoenix, Arizona
  • +16 more
Sep 9, 2021

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Worldwide (AG-120, Placebo for AG-120, AG-221)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2
  • Adelaide, Australia
  • +181 more
Aug 31, 2021

Healthy Volunteers Trial (AG-221, 14C AG-221)

Completed
  • Healthy Volunteers
  • AG-221
  • 14C AG-221
  • (no location specified)
Oct 26, 2018

Healthy Trial in Glendale (AG-221)

Completed
  • Healthy
  • AG-221
  • Glendale, California
    Parexel International
Oct 26, 2018

COVID-19, Infectious Disease Trial (JCXH-221, Active Comparator, Placebo)

Not yet recruiting
  • COVID-19
  • Infectious Disease
  • JCXH-221
  • +2 more
  • (no location specified)
Feb 22, 2023

HIV Trial in United States (gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • gp160 Vaccine (Immuno-AG)
  • gp160 Vaccine (MicroGeneSys)
  • Palo Alto, California
  • +3 more
Oct 27, 2021

Eating Behavior, Obesity, Appetitive Behavior Trial in London (0 kcal liquid, 600 kcal liquid meal, 1200 kcal liquid meal)

Recruiting
  • Eating Behavior
  • +2 more
  • 0 kcal liquid
  • +3 more
  • London, United Kingdom
    PsychoNeuroEndocrinology Research Group, Division of Psychiatry,
Aug 29, 2023